BioCentury | Jan 8, 2021
Management Tracks

Moderna hires chief commercial officer as it ramps up COVID vaccine rollout; plus MorphoSys, Silence, Verastem, Viking, Destiny and Allen Institute

...Sung Lee will succeed Jens Holstein as CFO, effective Feb. 2. Lee, who was CFO at Sangamo...
BioCentury | Dec 18, 2020
Product Development

Sangamo’s Macrae on where the gene editing field is headed: a BioCentury audio interview

...A conversation with Sangamo CEO Sandy Macrae on...
...consolidation in the coming years. Macrae, who joined Sangamo...
...about in Sangamo is adjacencies are essential. Sangamo's...
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...sciences officer and CTO, respectively. Lorget was the senior director of nonclinical safety evaluation at Sangamo...
...Therapeutics plc Monte Rosa Therapeutics Inc. Relmada Therapeutics Inc. Adicet Bio Inc. Abeona Therapeutics Inc. Erytech Pharma S.A. SparingVision Inc. Vertex Ventures HC Sangamo...
BioCentury | Oct 24, 2020
Emerging Company Profile

SparingVision’s line of sight to a mutation-agnostic gene therapy for ophthalmic disease

...Boissel was formerly EVP of corporate strategy at Sangamo...
...therapy company TxCell S.A. before its acquisition by Sangamo...
BioCentury | Oct 8, 2020
Product Development

First patient dosed in Phase III hemophilia A trial could narrow gap between Pfizer/Sangamo and BioMarin

...time as BioMarin’s two-year follow-up on Roctavian By  Amanda Micklus, Senior Biopharma Analyst Pfizer and Sangamo...
...occur in October 2021. With a potential BLA submission soon after, Pfizer Inc. (NYSE:PFE) and Sangamo...
...CRL in August 2020 recommending more evidence of durability. However, it’s possible that Pfizer and Sangamo’s...
BioCentury | Oct 7, 2020
Tools & Techniques

Doudna and Charpentier, CRISPR pioneers behind a spate of gene editing companies, awarded Nobel Prize

...developing other gene editing technologies such as Sangamo Biosciences Inc....
BioCentury | Sep 24, 2020
Product Development

The road ahead for the tau hypothesis of Alzheimer’s disease

...oligonucleotide therapy IONIS-MAPTRx. It also has a deal with Sangamo...
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...as SVP and head of T cell therapeutics. Rebar previously held the same role at Sangamo...
BioCentury | Aug 20, 2020
Regulation

What FDA’s request for a new endpoint means for BioMarin’s hemophilia gene therapy

...months, which would keep Roctavian ahead of its closest gene therapy competitor, giroctocogene fitelparvovec from Sangamo...
BioCentury | Aug 7, 2020
Deals

Billion-dollar Biogen deal gives Denali fuel to validate CNS delivery platform

...gained a new mechanism against existing Alzheimer’s and Parkinson’s targets via gene regulation technology from Sangamo...
Items per page:
1 - 10 of 493
BioCentury | Jan 8, 2021
Management Tracks

Moderna hires chief commercial officer as it ramps up COVID vaccine rollout; plus MorphoSys, Silence, Verastem, Viking, Destiny and Allen Institute

...Sung Lee will succeed Jens Holstein as CFO, effective Feb. 2. Lee, who was CFO at Sangamo...
BioCentury | Dec 18, 2020
Product Development

Sangamo’s Macrae on where the gene editing field is headed: a BioCentury audio interview

...A conversation with Sangamo CEO Sandy Macrae on...
...consolidation in the coming years. Macrae, who joined Sangamo...
...about in Sangamo is adjacencies are essential. Sangamo's...
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...sciences officer and CTO, respectively. Lorget was the senior director of nonclinical safety evaluation at Sangamo...
...Therapeutics plc Monte Rosa Therapeutics Inc. Relmada Therapeutics Inc. Adicet Bio Inc. Abeona Therapeutics Inc. Erytech Pharma S.A. SparingVision Inc. Vertex Ventures HC Sangamo...
BioCentury | Oct 24, 2020
Emerging Company Profile

SparingVision’s line of sight to a mutation-agnostic gene therapy for ophthalmic disease

...Boissel was formerly EVP of corporate strategy at Sangamo...
...therapy company TxCell S.A. before its acquisition by Sangamo...
BioCentury | Oct 8, 2020
Product Development

First patient dosed in Phase III hemophilia A trial could narrow gap between Pfizer/Sangamo and BioMarin

...time as BioMarin’s two-year follow-up on Roctavian By  Amanda Micklus, Senior Biopharma Analyst Pfizer and Sangamo...
...occur in October 2021. With a potential BLA submission soon after, Pfizer Inc. (NYSE:PFE) and Sangamo...
...CRL in August 2020 recommending more evidence of durability. However, it’s possible that Pfizer and Sangamo’s...
BioCentury | Oct 7, 2020
Tools & Techniques

Doudna and Charpentier, CRISPR pioneers behind a spate of gene editing companies, awarded Nobel Prize

...developing other gene editing technologies such as Sangamo Biosciences Inc....
BioCentury | Sep 24, 2020
Product Development

The road ahead for the tau hypothesis of Alzheimer’s disease

...oligonucleotide therapy IONIS-MAPTRx. It also has a deal with Sangamo...
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...as SVP and head of T cell therapeutics. Rebar previously held the same role at Sangamo...
BioCentury | Aug 20, 2020
Regulation

What FDA’s request for a new endpoint means for BioMarin’s hemophilia gene therapy

...months, which would keep Roctavian ahead of its closest gene therapy competitor, giroctocogene fitelparvovec from Sangamo...
BioCentury | Aug 7, 2020
Deals

Billion-dollar Biogen deal gives Denali fuel to validate CNS delivery platform

...gained a new mechanism against existing Alzheimer’s and Parkinson’s targets via gene regulation technology from Sangamo...
Items per page:
1 - 10 of 493